Statera Biopharma, Inc. (STAB) saw a decrease of 16.03% in premarket because the company announced the pricing of $2.0 Million Registered Direct Offering. However, the last trading session closed at $1.31 with a decrease of 2.96%.
$2.0 Million Registered Direct Offering by STAB – What’s up?
STAB announced on 6th February 2022 that it had signed into a securities sales contract with a specific institutional investor to buy about $2.0 million in ordinary shares and warrants in a regulated direct offering. Moreover, the Company’s total earnings from the authorized direct offering are estimated to be around $2.0 million.
Phase 3 Clinical Trial Protocol by STAB – What’s going on?
On 29th December 2021, STAB announced that the company has submitted Phase 3 clinical trial protocol for STAT-201 to FDA. STAT-201 is an immune modulator that will restore mucosal healing and intestinal barrier function. With endoscopies, Phase 2 research showed proof of concept, safety, and remission in 67 percent of individuals, as well as 43 percent of genuine mucosal healing. Moreover, the experiment had no significant side effects. The FDA has also designated STAT-201 as an orphan medication for the treatment of CD in children.
Chronic diarrhea, stomach pain, and rectal bleeding are all signs of CD. It was once thought to be a rare condition among children and adolescents. Later it was recognized as one of the most serious chronic diseases affecting children and adolescents. Nearly a third of all CD patients are under the age of 20. The signs and symptoms are unpredictably unpredictable, causing physical, emotional, and financial hardship. Despite current medications, people with CD continue to have flares, smoldering illness, or terrible side effects, necessitating the development of novel treatment alternatives.
Now what?
STAB has submitted the Phase 3 clinical trial plan which is a critical milestone in the research program. Furthermore, growth failure, nutrition, late puberty, and bone demineralization are frequent in children with Crohn’s Disease, in addition to the common GI symptoms. Lastly, STAT-201 has the potential to bring significant physical and emotional relief to Crohn’s Disease patients in their adolescent years.
